Skip to content

Kiniksa Pharmaceuticals International

US · KNSA #1938 by market cap Listed 2018
93.90 +0.36 +0.38%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $74
    Market Newswire · 2026/7/13
  • Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$14.33 Million in Common Stock
    Market Newswire · 2026/11/7
  • Rating change
    A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $57 to $71
    Market Newswire · 2026/4/29
  • Rating change
    Citi Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/15
  • Rating change
    Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $101
    Market Newswire · 2026/10/28
  • Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$37.4 Million in Common Stock
    Market Newswire · 2026/11/4
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72
    Market Newswire · 2026/6/29
  • Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$8.94 Million in Common Stock
    Market Newswire · 2026/11/4
  • Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$9.63 Million in Common Stock
    Market Newswire · 2026/11/4
  • Rating change
    A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $87 to $107
    Market Newswire · 2026/7/30
  • Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$3.39 Million in Common Stock
    Market Newswire · 2026/11/4
  • Rating change
    Wells Fargo Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $87
    Market Newswire · 2026/9/30
  • Rating change
    Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $90
    Market Newswire · 2026/7/30
  • Rating change
    Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $75
    Market Newswire · 2026/7/23
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $58
    Market Newswire · 2026/4/16
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $59
    Market Newswire · 2026/4/29
  • Rating change
    J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $122
    Market Newswire · 2026/10/30
  • Rating change
    Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $110
    Market Newswire · 2026/10/29
  • Rating change
    J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72
    Market Newswire · 2026/5/4
  • Rating change
    CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $98
    Market Newswire · 2026/10/30
  • Rating change
    Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $53
    Market Newswire · 2026/2/26
  • Form 144 | Kiniksa Pharmaceuticals International(KNSA.US) Officer Proposes to Sell 4.56 Million in Common Stocks
    Market Newswire · 2026/10/31
  • Rating change
    J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/3/14
  • Form 144 | Kiniksa Pharmaceuticals International(KNSA.US) Officer Proposes to Sell 9.75 Million in Common Stocks
    Market Newswire · 2026/10/31
  • Rating change
    CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $62
    Market Newswire · 2026/2/26

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Kiniksa Pharmaceuticals International discussion 0 comments

Add a comment